Investing in AI feels like a gamble...
It doesn't have to be.
Meet ARIA™
Our proprietary AI Risk Investment Audit modeled on the rigor of FDA review.
ARIA™ reveals critical red flags in medical AI that will cost you millions if overlooked.
Unfiltered. Unbiased. Unsparing.
“In health AI, the stakes are too high for shortcuts.
That’s why we created ARIA™, our proprietary AI audit framework, to separate hype from reality. We interrogate the science, stress-test algorithms, study the balance of performance metrics, and flag AI flaws standard diligence procedures can often miss. With SkyMedAI, you invest—or walk away—with all the facts in hand.”
We Partner With:
VC firms, Private Equity, and Family Offices 
Health AI investments require specialized auditing. From pre-investment evaluation to ongoing portfolio support, we bring deep clinical, scientific, and machine learning expertise to deliver the unbiased truth investors need before making a move.
Without specialized auditing, you're blind to critical risks: compromised training data, hidden algorithmic biases, model drift vulnerabilities, and inadequate safety guardrails. We make the invisible visible—so you invest with eyes wide open.
Impressive demos rarely survive deployment. We validate what pitch decks won't show: dataset quality, algorithmic robustness, hidden biases, and drift risks that cause AI to fail when it meets the real world.
How ARIA™ Works
A reality check before you write a check
1. Data Integrity & Bias Audit
We work with investors who refuse to bet millions on pitch deck theater. The risk? Flawed training data leads to AI that fails approval and tanks valuations. Without independent dataset verification, you’re funding write-offs, not exits.
- Assess if the AI foundation is solid before you write the check
- Trace AI data sources through publications, pilot trials, supplementary records, and validation studies
- Audit 15+ quality dimensions, including selection bias, fairness gaps, labeling integrity, and ground truth validity
✓ Go/No-go decision
Confidence to invest or walk away before capital burns
✓ Risk mitigation
Unfiltered, bias-free evaluation exposing hidden vulnerabilities standard DD overlooks
2. Algorithm Performance & Drift Analysis
Impressive AI performance on pitch decks can be misleading if not put in the right context. And AI demos rarely survive in the real world. Without validation of testing protocols, you’re trusting results that collapse on contact with reality.
- Audit scientific integrity, data contamination, leakage, and biases
- Spot performance failures before regulators or patients do
- Verify AI works beyond demos on messy, unfriendly, real-world data
✓ Investment protection
Catch methodological fraud and sloppy algorithms before they become a liability
✓ Invest in the right companies
Get the full clinical evidence picture, not just the highlight reel
3. Clinical Validation & Risk Assessment
Inadequate clinical validation threatens your investment. Poor evidence quality leads to regulatory failure, market rejection, and safety liabilities—risks that tank valuations before deployment.
- Validate claims against published literature and real-world data
- Identify data analysis flaws and validation gaps
- Review safety protocols and adverse event monitoring
✓ Investment protection
Avoid deals built on weak or misleading clinical foundations
✓ Commercialization insight
Early visibility into validation gaps that could delay market entry or regulatory approval
✓ Competitive advantage
Identify companies with genuinely robust clinical evidence others overlook
4. AI Safety & Guardrails Inspection
AI systems without proper safety guardrails can produce dangerous outputs or fail unpredictably. These failures create patient harm, trigger regulatory action, and cause reputational damage that can sink both the company and your investment.
- Perform rigorous safety and guardrail inspection
- Review human-in-the-loop protocols and override capabilities
- Test edge cases and failure scenarios to expose safety vulnerabilities
✓ High-stakes assurance
Verified guardrails exist for critical clinical decision points
✓ Investment protection
Prevention of costly failures that could eliminate portfolio value
5. Portfolio Foresight & Future-Proofing
Your portfolio’s AI faces two threats: performance decay and rapid obsolescence. Models degrade, regulations shift, but the real risk is innovation velocity. Today’s state-of-the-art becomes tomorrow’s legacy tech. Without foresight, you risk losses or mediocre returns.
- Guide portfolio companies through system upgrades, market shifts, and threats that risk obsolescence
- Proactively monitor AI performance to catch model drift, emerging biases, and degradation before they become costly
- Track regulatory shifts before they become enforcement actions
✓ Future-proof while capturing upside
Identify emerging AI trends early—capitalize on opportunities and protect against obsolescence
✓ Maximize exit value
Ensure portfolio companies stay competitive, compliant, and acquisition-ready as AI evolves
Originally built for investors, ARIA™ now serves hospitals, pharma, medtech, and startups who refuse to gamble on AI before it's proven.
Close
Close
Close